Emergex Vaccines
We work on addressing some of the world’s most immediate health threats including viral diseases such as Dengue Fever, Zika, Ebola and pandemic Flu, as well as serious intra-cellular bacterial infections, and we have a growing pipeline of vaccine candidates.
Latest news
- Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine 5 January 2021
- Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases 18 November 2020
- Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells 15 September 2020